CRIS Current Research Information System

POERIO, ANGELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.467
AS - Asia 1.193
EU - Europa 1.039
AF - Africa 90
Continente sconosciuto - Info sul continente non disponibili 71
SA - Sud America 57
Totale 3.917
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.450
VN - Vietnam 341
CN - Cina 293
SG - Singapore 273
GB - Regno Unito 257
SE - Svezia 170
DE - Germania 125
IT - Italia 118
JP - Giappone 83
FR - Francia 68
UA - Ucraina 66
HK - Hong Kong 61
NL - Olanda 61
IN - India 60
BR - Brasile 41
RU - Federazione Russa 40
IE - Irlanda 34
TG - Togo 33
CI - Costa d'Avorio 25
KR - Corea 20
FI - Finlandia 18
ZA - Sudafrica 17
CH - Svizzera 16
EE - Estonia 14
JO - Giordania 14
CA - Canada 12
BG - Bulgaria 11
BE - Belgio 10
BD - Bangladesh 9
PL - Polonia 9
GR - Grecia 8
IR - Iran 7
PH - Filippine 7
AR - Argentina 5
CL - Cile 5
ES - Italia 5
SC - Seychelles 5
TR - Turchia 5
NG - Nigeria 4
EC - Ecuador 3
MX - Messico 3
TH - Thailandia 3
TW - Taiwan 3
AT - Austria 2
CO - Colombia 2
IQ - Iraq 2
KE - Kenya 2
MA - Marocco 2
MY - Malesia 2
PK - Pakistan 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
XK - ???statistics.table.value.countryCode.XK??? 2
AE - Emirati Arabi Uniti 1
CY - Cipro 1
CZ - Repubblica Ceca 1
EG - Egitto 1
ET - Etiopia 1
ID - Indonesia 1
IL - Israele 1
JM - Giamaica 1
LB - Libano 1
LT - Lituania 1
MD - Moldavia 1
MN - Mongolia 1
PY - Paraguay 1
RO - Romania 1
RS - Serbia 1
SV - El Salvador 1
Totale 3.848
Salva come PNG Salva come JPEG
Città #
Southend 216
Singapore 192
Chandler 180
Ashburn 152
Fairfield 108
Tokyo 74
Woodbridge 70
Houston 65
Wilmington 60
Dong Ket 59
Ho Chi Minh City 59
Seattle 57
Ann Arbor 56
San Jose 56
Hefei 54
Hong Kong 53
Hanoi 46
Jacksonville 46
Dallas 45
Princeton 39
Cambridge 35
Beijing 34
Dublin 34
Lomé 33
Santa Clara 33
Boardman 28
New York 27
Abidjan 24
Turin 22
Falls Church 20
Nanjing 20
Westminster 19
Padova 18
Helsinki 17
Lauterbourg 16
Seoul 16
Munich 15
Amman 14
Bern 14
Los Angeles 14
Berlin 12
Buffalo 12
Da Nang 12
Falkenstein 12
Jinan 12
Sofia 11
Brussels 10
Chicago 10
Haiphong 9
Warsaw 9
Council Bluffs 8
Saint Petersburg 8
Changsha 7
Hangzhou 7
Jiaxing 7
Milan 7
Nanchang 7
Orem 7
San Diego 7
Taizhou 7
Bengaluru 6
Frankfurt am Main 6
Phoenix 6
Shenyang 6
Bremen 5
Des Moines 5
Guangzhou 5
Hebei 5
Medford 5
Pune 5
Tianjin 5
Zhengzhou 5
Bologna 4
Chengdu 4
Chiyoda-ku 4
Dearborn 4
Florence 4
Mahé 4
Mülheim 4
Shanghai 4
São Paulo 4
Washington 4
Abeokuta 3
Amsterdam 3
Atlanta 3
Boston 3
Can Tho 3
Chandigarh 3
Haikou 3
Hamamatsu 3
Istanbul 3
Johannesburg 3
London 3
Montreal 3
Mumbai 3
Ningbo 3
Qingdao 3
Rome 3
San Venanzo 3
Stockholm 3
Totale 2.479
Salva come PNG Salva come JPEG
Nome #
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 356
Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies 314
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies 304
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia 278
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia 258
Denaturing-HPLC-based assay for detection of ABL mutations in Chronic Myeloid Leukemia patients resistant to Imatinib 249
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. 209
Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. 193
Contribution Of ABL Kinase Domain Mutations To Imatinib Resistance In Different Subsets Of Philadelphia-Positive Patients. By The GIMEMA Working Party On Chronic Myeloid Leukemia 190
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response 190
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. 175
Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia on Behalf of the GIMEMA CML WP. 172
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. 171
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. 167
Low level mutations in the Bcr-Abl kinase domain may already be detected at diagnosis both in patients with Philadelphia-positive acute lymphoblastic leukemia and in patients with chronic phase chronic myeloid leukemia 165
Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome 107
Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis 102
Pancreatic enzymes elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure 98
null 85
null 77
null 57
Totale 3.917
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.799
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.799
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022393 0 6 34 46 36 28 9 44 12 29 78 71
2022/2023587 72 116 31 70 36 45 14 24 94 14 50 21
2023/2024211 5 21 5 18 12 90 23 15 2 3 12 5
2024/2025457 13 56 32 36 58 38 27 19 1 65 25 87
2025/20261.025 79 83 126 59 149 66 93 20 218 76 31 25
2026/202741 22 19 0 0 0 0 0 0 0 0 0 0
Totale 3.917